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Abstract: Chronic obstructive pulmonary disease (COPD) is a multicomponent disorder 
that leads to substantial disability, impaired quality of life, and increased mortality. Although 
the majority of COPD patients are first diagnosed and treated in primary care practices, there 
is comparatively little information on the management of COPD patients in primary care. 
A web-based pilot survey was conducted to evaluate the primary care physician’s, or general 
practitioner’s (GP’s), knowledge, understanding, and management of COPD in twelve 
  territories across the Asia-Pacific region, Africa, eastern Europe, and Latin America, using a 
10-minute questionnaire comprising 20 questions and translated into the native language of 
each participating territory. The questionnaire was administered to a total of 600 GPs (50 from 
each territory) involved in the management of COPD patients and all data were collated and 
analyzed by an independent health care research consultant. This survey demonstrated that the 
GPs’ understanding of COPD was variable across the territories, with large numbers of GPs 
having very limited knowledge of COPD and its management. A consistent finding across all 
territories was the underutilization of spirometry (median 26%; range 10%–48%) and reliance 
on X-rays (median 14%; range 5%–22%) for COPD diagnosis, whereas overuse of blood tests 
(unspecified) was particularly high in Russia and South Africa. Similarly, there was considerable 
underrecognition of the importance of exacerbation history as an important factor of COPD and 
its initial management in most territories (median 4%; range 0%–22%). Management of COPD 
was well below guideline-recommended levels in most of the regions investigated. The findings 
of this survey suggest there is a need for more ongoing education and information, specifically 
directed towards GPs outside of Europe and North America, and that global COPD guidelines 
appear to have limited reach and application in most of the areas studied.
Keywords: COPD, questionnaire, survey, guidelines
Introduction
Chronic obstructive pulmonary disease (COPD) is an important multicomponent 
chronic lung disorder that causes substantial disability, significantly impairs the 
health-related quality of life, and increases the risk of death in individuals with 
moderate to severe airway obstruction.1–8 Epidemiologic evidence suggests that 
prevalence of COPD ranges from 4% to 20% in adults over 40 years of age, with 
latest estimates from the World Health Organization indicating about 210 million 
people being affected worldwide.4 However, it is likely that this number is underes-
timated as a consequence of differences in diagnostic criteria employed and because 
the disease is often not diagnosed or is misdiagnosed in the early stages.4,5 There is a 
considerable difference in the prevalence of COPD between low- to middle-income 
and high-income countries.4
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The Global Initiative for Chronic Obstructive Lung 
Disease (GOLD)5 suggests that although COPD is not a 
curable disease, it is nevertheless preventable and treatable. 
However, a constraint in optimal management of COPD 
patients is that the majority of COPD patients are usually 
first seen and treated by primary care physicians, who 
may or may not, for a variety of reasons, diagnose or treat 
patients appropriately.9,10 Indeed, despite the availability 
of international5,7,11 and national clinical guidelines for the 
management of COPD,12–15 the disease commonly remains 
undiagnosed,15,16 or is diagnosed only at an advanced stage 
when the clinical symptoms become apparent and the 
  disease is associated with substantial end-organ damage.16–18 
F  urthermore, once COPD is diagnosed, it is often undertreated 
or is treated inappropriately.16,19,20 Misdiagnosis of COPD is 
also quite common,20–22 with up to 25% of patients over 
40 years old with COPD being labeled as having asthma21,22 
and, conversely, about 7% of patients with asthma being 
labeled as having COPD.20 Moreover, many patients 
identified as COPD patients using the COPD International 
C  lassification of Diseases, 9th Revision, Clinical Modification 
diagnostic codes do not have airflow obstruction when they 
undergo spirometry.23
Information available to date on the management of 
COPD patients in primary care is limited and mostly comes 
from Western countries with established national and/or 
regional management programs for COPD. In view of these 
findings, the authors undertook a study to survey general 
practitioners (GPs) in non-European Union/non-US territories 
across the Asia-Pacific region, Africa, eastern Europe, and 
Latin America in order to understand how GPs approached 
COPD diagnosis and treatment in these regions.
Methods
A group of physicians from Argentina, Australia, Brazil, 
China, Hong Kong, Japan, Mexico, Russia, South Africa, 
South Korea, Taiwan, and Turkey who were experts in the 
field of chronic respiratory diseases was assembled in March 
2010, through an unrestricted grant from GlaxoSmithKline. 
This group was provided with a broad-based brief to explore 
the management of COPD patients by GPs in their respective 
territories. Following initial group discussions, it became 
clear that there was a common perception that poor manage-
ment, including late diagnosis and inappropriate treatment 
of COPD patients, was a major problem globally. Moreover, 
this appeared to be driven predominantly by the clinical 
practice of GPs; however, there were little data to confirm 
this observation.
To test this hypothesis, a pilot survey was conducted to 
evaluate the GPs’ knowledge, understanding, and manage-
ment of COPD, irrespective of the number of years of their 
experience as practicing physicians, in each of the twelve 
territories represented by the members of the expert group. 
A short and easy-to-administer questionnaire (Appendix 1) 
comprising 20 questions was developed by informative dis-
cussion and general consensus among members of the expert 
group. Prior to finalization, the members of the expert group 
translated the questionnaire into the native languages of their 
respective territories, and these translated questionnaires 
were then validated by piloting among small groups of GPs 
and professional physicians in the respective territories. The 
final translated and validated questionnaires were then admin-
istered in the different territories as a web-based survey.
Synovate Healthcare, London, UK (an independent health 
care research consultancy firm specializing in such surveys) 
recruited participants from a panel of self-registered GPs 
from different regions across each of the twelve territories, 
creating and managing the panel between 2006 and 2011. All 
participants responded to a request to participate in the study 
and all were nominally compensated for their time, with a 
payment of between £14 and £44, depending on territory.
A total of 813 questionnaire surveys were conducted, of 
which the first 50 fully completed questionnaires for each 
territory were selected, and the remaining questionnaires 
excluded from the final analysis (109 incomplete question-
naires and 104 fully completed questionnaires after the 
quota was reached). A total of 600 responses from GPs were 
included in this analysis. The sample size was determined 
based on advice from Synovate Healthcare, who indicated 
that, based on experience of such studies, n = 30/territory was 
enough to get a “signal,” and thus n = 50/territory would be 
appropriate for the study.
Data from all participants were collated in a dedicated 
database, which was also set up and managed by Synovate 
Healthcare.
Results
Table 1 shows the demographics of the GP participants. 
Assessment of age distribution indicated that Mexico and 
R  ussia had the youngest GPs; for example, 92% of GPs in 
Mexico were under 40 years of age. In contrast, Argentina 
(52%) and Australia (46%) had the highest numbers of GPs 
over 50 years of age, with 2% of GPs from Argentina being 
older than 70 years. Similarly, 6% of GPs from Hong Kong 
were older than 70 years. The majority of GPs surveyed were 
male (overall mean of 73%), with Japan and South Korea 
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  having almost completely male GP practices.   However, 
females comprised the majority of the GPs in China and 
  Russia. Although the overall mean number of years in   practice 
for the sample was 15.9 years, assessment by   territory indi-
cated that the mean number of years in practice was directly 
  correlated with the age of the GPs. Thus, the GPs from Mexico 
were the least experienced (mean of 5.7 years) and the GPs 
from Argentina (mean of 23.3 years) and   Australia (mean of 
22.5 years) were the most experienced.
Understanding of prevalence  
and risk factors
The GPs’ understanding of the prevalence of and risk fac-
tors associated with COPD was assessed according to their 
responses to questions 7 and 8, respectively, from the survey 
questionnaire (Appendix 1). While a mean of 35.5% of the 
GPs (range 8%–64%) surveyed reported a prevalence rate of 
over 15% in their country, a mean of 10.3% of the GPs (range 
0%–24%) reported a prevalence rate below 5% (Figure 1). 
Moreover, relatively large numbers of GPs from Argentina 
(14%), China (12%), and Taiwan (16%) did not have any idea 
of the prevalence of COPD in their respective territories.
Assessment of the GPs’ knowledge of the major risk 
factors associated with COPD showed that although the 
majority of the GPs (94%) rated smoking to be the top risk 
factor, 38% of GPs surveyed also rated asthma to be the next 
most important risk factor across all territories. Interestingly, 
although many clinicians regard hereditary factors as being 
important, only 9% of the GPs also considered this to be the 
case. Furthermore, 6% of GPs also considered tuberculosis 
to be an important risk factor for COPD.
Diagnosis
The GPs’ practices for diagnosis of COPD were assessed 
according to their responses to Question 12 from the survey 
questionnaire (Appendix 1). Symptoms and spirometry were 
the most frequently reported routine tools used to diagnose 
subjects with COPD (mean of 56.5% of first or second mentions 
for symptoms, with a range of from 26% [South Africa] to 
76% [Argentina/Hong Kong]; mean of 52.8% of first or 
second mentions for spirometry, with a range of from 
18% [Turkey] to 84% [Australia]) (Table 2). Interestingly, 
GPs from South Africa tended to underreport the use of 
symptoms and spirometry (26% of first and second mentions 
for   symptoms and 20% of first and second mentions for 
spirometry) and overreport the use of blood tests (50% of first 
and second mentions) as routine diagnostic tools for COPD, 
compared with their peers from other territories (Table 2). 
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However, when considering all mentions of routine tools, 
instead of only first and second mentions, the reported use 
of the chest X-ray became prominent in all territories and 
actually exceeded the reports for spirometry and/or symptoms 
in five of the twelve territories (Hong Kong, Mexico, Russia, 
South Africa, South Korea) surveyed (Table 2). Moreover, the 
survey demonstrated that the underutilization of spirometry 
in most territories was apparent despite the GPs having ready 
access to the technique (Table 3).
Initiation and management of treatment
The GPs’ practices for initiation and management of 
treatment for COPD were assessed according to their 
responses to questions 13 and 14, respectively, from the 
survey questionnaire (Appendix 1). Although symptoms and 
spirometry often guided the GPs’ choice of initial treatment 
in the survey, there was underrecognition of the importance 
of exacerbation history as an important factor of COPD and 
its initial management in most countries (median 4%; range 
0%–8%) apart from China (22%). Indeed, exacerbation history 
was not mentioned as one of the three most important factors 
in any territory other than Brazil and Taiwan. Similarly, 
exacerbation history was not even considered to be important 
for the ongoing management of patients by the majority of the 
physicians surveyed in four of the twelve territories, including 
China, Hong Kong, Japan, and South Africa (Figure 2).
Reference to guidelines
The GPs’ practices for use of COPD guidelines were assessed 
according to their responses to questions 15–17 from the 
survey questionnaire (Appendix 1). Roughly two out of three 
GPs in the sample reported that COPD guidelines informed 
their management practices (Figure 3). Physicians reported 
the use of a wide variety of guidelines, of which institutional 
and organizational guidelines were used more frequently 
than the GOLD guidelines.5 Indeed, the GOLD guidelines5 
were not mentioned by the sample of GPs from China, South 
Africa, or Turkey, and the International Primary Care and 
Respiratory Group COPD management guidelines11 were 
not mentioned at all.
While the GPs from Hong Kong and Turkey were less 
likely to be influenced by guidelines in the management 
of COPD, overall non-guideline-informed management of 
COPD was reported to be either a consequence of nonavail-
ability of the guidelines to large numbers of the GPs surveyed 
in most of the territories or because the GPs considered the 
guidelines to be too long or not relevant (Figure 3).
Discussion
The generally accepted global prevalence for COPD in 
adults aged 40 years and over ranges between 7% and 15%, 
according to the population-based BOLD, PLATINO, and 
Asia-Pacific studies.24–27 This survey has demonstrated 
that the GPs involved in the survey tended to overestimate 
prevalence figures, despite a general consensus that COPD 
is underdiagnosed and undertreated. While population-based 
surveys are an important tool to provide real estimates of 
prevalence, it is interesting to note that there still appears to 
be a wide variation of awareness of these data at the GP level 
in territories such as Australia, Brazil, China, Hong Kong, 
Japan, South Africa, and Turkey, where population-based 
prevalence estimates have been conducted.24–27
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Figure 1 Perceived prevalence of chronic obstructive pulmonary disease (COPD) in each territory.a
Notes: aResults based on Question 7 from the COPD survey questionnaire: In your opinion, what is the prevalence of COPD in your country? (N = 600).
Abbreviation: DK, don’t know.
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Table 3 Access to and use of spirometry as the first diagnostic 
tool for chronic obstructive pulmonary disease (COPD) in each 
territory
Territory GP access to  
spirometry (%)a
GP use of spirometry  
as first diagnostic tool   
for COPD (%)b
Argentina 80 22
Australia 94 48
Brazil 92 34
China 64 40
Hong Kong 46 10
Japan 64 40
Mexico 42 34
Russia 96 22
South Africa 78 12
South Korea 60 40
Taiwan 86 26
Turkey 10 12
Notes: aResults based on Question 11 from the COPD survey questionnaire: in 
your practice, which of the following do you have easy access to? (N = 600); bresults 
based on Question 12 from the COPD survey questionnaire: What do you routinely 
use to diagnose COPD in your practice? (N = 600).
Abbreviation: GP, general practitioner.
The GOLD guidelines suggest that symptoms, 
  spirometry, and exacerbation history are the most impor-
tant features of the assessment of COPD patients,5 with 
spirometry particularly being advocated by international 
guidelines as a key aspect of diagnosis for COPD.5,11 The 
use of spirometry as a routine diagnostic tool was mentioned 
frequently in the survey, yet much research suggests that 
spirometry is underutilized by GPs. It is unclear if survey 
respondents provided answers based on best practice rather 
than on the reality of care. In Turkey, where access to 
spirometry is limited by the health care system to specialty 
care, the sample did reflect this reality in the GPs’ responses. 
The overall finding for low utilization of spirometry as a 
diagnostic tool for COPD in the survey is in accordance 
with the findings of two recent prospective cross-sectional 
studies that investigated practice patterns of primary care 
physicians with experience of managing COPD patients.16,28 
However, the authors of the present survey were surprised 
by the frequency of mentions of chest X-rays as diagnostic 
tools, with chest X-rays mentioned more than spirometry 
in some territories.
Although the authors know of no blood test currently 
available and recognized by the medical community for diag-
nosing COPD, the use of blood tests as a speculative answer 
to the question on routine diagnostic tools was included in 
the survey to determine the GPs’ response. Interestingly, the 
survey demonstrated that in a large minority of the territories 
sampled, blood tests were indeed mentioned frequently, 
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with 50% or more of GPs using this as a diagnostic tool for 
COPD. Moreover, there appeared to be a negative correla-
tion between the frequency of mention of blood tests and the 
frequency of mention of guideline-informed management 
of the disease, suggesting a gross deficiency in the COPD 
management practice of these GPs.
A history of exacerbations is a predictor of risk for 
future exacerbations, more rapid decline in lung function, 
poorer quality of life, and increased mortality.29,30 In this 
survey, a history of exacerbations was not cited in most 
territories as an important consideration for the initiation 
of treatment and was not considered as important by the 
majority of survey respondents in Japan, Hong Kong, and 
South Africa. It is possible that in the current absence of a 
universally accepted definition of COPD exacerbation,31–33 
most GPs did not fully understand what characterized an 
exacerbation of COPD and therefore did not give much 
importance to its history.
Argentina Australia Brazil China
76%
82%
84% Symptoms
Spirometry
Exacerbation 
history 88%
80%
92%
84%
64%
76%
0% 100%
48%
76%
68%
44%
40%
76% Symptoms
Spirometry
Exacerbation 
history
32%
72%
72%
56%
62%
74%
0% 100%0 % 100% 0% 100%
0% 100% 0% 100%0 % 100% 0% 100%
0% 100% 0% 100%0 % 100%0 % 100%
Hong
Kong
Japan Mexico
66%
68%
66%
Symptoms
Spirometry
Exacerbation 
history
28%
64%
68%
72%
80%
84%
82%
28%
68%
Russia
South
Africa
54%
46%
64%
South
Korea
Taiwan Turkey
Figure 2 Ongoing treatment of chronic obstructive pulmonary disease (COPD) by general practitioners in different territories, based on symptoms, spirometry, and 
exacerbation history.a
Note: aResults based on Question 14 from the COPD survey questionnaire: in your practice, which of the following are important when deciding the ongoing treatment of 
a COPD patient? (N = 600).
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Limitations
This survey is limited in several respects. The sample size 
was relatively small and might not be representative of 
the general GP population in larger countries with diverse 
regional and/or cultural differences (eg, China and Russia). 
However, as far as the authors are aware, it provides the only 
data that address these issues within the regions, and therefore 
it forms an important reference base for further research. 
Participants were recruited from a select panel of registered 
GPs, using a web-based approach. It is possible that survey 
respondents provided answers based on best care rather than 
on the   reality of their practice. However, despite the lack of 
rigorous sampling strategy, there is consistency in several 
aspects of this report, across all territories surveyed, and the 
data form the basis for further, more directed studies in a 
larger sample size in each territory.
Conclusion
This survey was conducted in territories where the views and 
beliefs of GPs are not usually assessed in global surveys, and 
therefore the results reflect opinions of frontline physicians 
in a variety of situations. The findings of this survey suggest 
that there appears to be a need for more ongoing education 
and information, specifically directed towards GPs outside of 
Europe and North America, and that global COPD guidelines 
appear to have limited reach and application in these areas. In 
particular, there appears to be a need to increase awareness 
of the importance and use of spirometry to confirm a COPD 
diagnosis and to increase awareness of exacerbations and 
their importance in managing COPD. Furthermore, there 
appears to be a need for both providing easier access to the 
guidelines and simplifying the guidelines, of which the latter 
should be done in consultation with GPs, in order that the 
guidelines are seen as being able to add value to their prac-
tice of managing COPD patients. The results of this survey 
clearly suggest that a larger prospective study of the beliefs 
and attitudes of GPs in non-Western countries is warranted 
to better establish the information on the practices/knowledge 
of GPs in those regions.
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Figure 3 Percentage of general practitioners managing chronic obstructive pulmonary disease (COPD) patients according to guidelines.
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Appendix 1: COPD survey questionnaire
Q1.	 Country of practice?
_________________
Q2.	 Age (years)?
,20 (END SURVEY)
21–30
31–40
41–50
51–60
61–70
70+
Q3.  Gender?
Male
Female
Q4.    Years of practice? (Open question, limit to two characters)
_______________________________________________
Q5.    Number of patients you see a month? (Open question, limit to 999 as maximum)
_________________________________________________________________
Q6.    What percentage of the answer to Q5 are COPD (also referred to as emphysema or chronic bronchitis) patients? (PN: 
0%–100%)
_____________________________________________________________________________________________
Q7.    In your opinion, what is the prevalence of COPD in your country?
0%–5%
6%–10%
11%–15%
16%–20%
21%–25%
26%–30%
31%–35%
36%–40%
41%–45%
46%–50%
.50%
Don’t know
Q8.    What are the three major risk factors associated with COPD in your country?
Aging
Asthma
Indoor air pollution
Occupational exposure
Outdoor air pollution
Hereditary
Tobacco smoke
Tuberculosis
Don’t know
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  Q9.    In your opinion, what are the most common comorbid diseases associated with COPD? (Please give up to three 
answers.)
1.	 _________________________________________________________________________________________
2.	 _________________________________________________________________________________________
3.	 _________________________________________________________________________________________
Q10.    Do COPD exacerbations have any of the following long-term effects? (You may choose between one and five 
answers.)
Increase rate of decline in lung-function
Increase rate of mortality
Increase risk of cancer
Weight gain
Worsening of quality of life
Don’t know
Q11.  In your practice, which of the following do you have easy access to?
Arterial blood gases
Blood test
Chest X-ray
CT scan
Spirometry
Oximetry
Other: __________________________________________________
Q12.    What do you routinely use to diagnose COPD in your practice? (If you choose more than one option then rank in 
order of importance.) (PN: If respondent chooses more than one option then rank in order of importance.)
Arterial blood gases
Blood test
Bronchodilator response
Chest X-ray
CT scan
Oximetry
Spirometry
Symptoms
Other: ______________________________________________________________________________________
Q13.    In your practice, please rank in order of importance which of the following you consider when deciding on the initial 
treatment of a COPD patient?
Age
Chest X-ray
Comorbid diseases
CT scan
Environmental control including smoking cessation
Exacerbation history
Exercise limitation
Oximetry
Spirometry
Sputum examination
Symptoms
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Q14.    In your practice, which of the following are important when deciding the ongoing treatment of a COPD patient?
Age
Chest X-ray
Comorbid diseases
CT scan
Environmental control including smoking cessation
Exacerbation history
Exercise limitation
Oximetry
Spirometry
Sputum examination
Symptoms
Q15.    Is your management of COPD informed by any guidelines?
Yes
No
Q16.  If yes, which guidelines do you follow?
________________________________
Q17.  If no, why do you not follow COPD guidelines?
Not available
Too long
Not relevant
Other: _________________________________
Q18.    What are the reasons for you to refer a patient to a respiratory physician? (You may choose more than one answer.)
  Appropriate treatment can only be prescribed by respiratory physician
Patient has not responded to therapy
Patient requests it
Patient requires oxygen therapy
Patient requires rehabilitation
Patient requires special education
You are unsure about the diagnosis
Other: ______________________________________________________________________________________
Q19.    What proportion of your COPD patients cannot access the treatment you wish to prescribe them?
None (END SURVEY)
1%–25%
26%–50%
51%–75%
76%–100%
Don’t know (END SURVEY)
Q20.    If your answer is one of the numerical options (ie, 1%–25%, 26%–50%, 51%–75%, or 76%–100%), why do your 
COPD patients not have access to their treatment?
Guidelines/regulations
Not on hospital/clinic formulary
Patient preference
Too expensive
Other: ______________________________________________________________________________________
END OF SURVEY
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